Amplia Therapeutics (INNMF) AI Stock Analysis

Amplia Therapeutics

(Other OTC:INNMF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong equity cushion and low leverageEquity represents most of the asset base, while debt remains modest, giving Amplia a meaningful solvency cushion. This balance-sheet structure can provide greater flexibility to fund development and absorb operating volatility than a highly leveraged biotechnology company.

Negative Factors

Revenue has fallen to zeroThe collapse to zero revenue shows that Amplia currently lacks a dependable commercial or recurring revenue stream. That leaves the company reliant on financing or other sources of capital to support operations and clinical development, increasing execution pressure over the next several quarters.

Amplia Therapeutics (INNMF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $27.72M
Dividend Yield: ―
Average Volume (3M): 35.15K
Price to Earnings (P/E): -5.0
Beta (1Y): -1.47
Revenue Growth: ―
EPS Growth: 20.29%
Country: US
Employees: 8
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Amplia Therapeutics Business Overview & Revenue Model

Company Description

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of F...

Amplia Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

INNMF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:NEU	74Outperform	AUD 2.58B	128.62	6.03%	0.74%	-68.00%	-86.31%
AU:ZLD	52Neutral	AUD 5.95M	-1.56	80.84%	―	―	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:PAR	47Neutral	AUD 153.48M	-1.61	-1189.87%	―	53.78%	-206.24%
AU:ATH	44Neutral	AUD 60.72M	-2.40	-48.25%	―	―	-16.21%
AU:ENP	43Neutral	AUD 50.66M	-13.48	-63.60%	―	―	29.55%

* Healthcare Sector Average

Performance Comparison

INNMF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
INNMF	Amplia Therapeutics Ltd.	0.05	-0.03	-32.50%
AU:ENP	Tryptamine Therapeutics Limited	0.03	-0.01	-18.42%
AU:NEU	Neuren Pharmaceuticals Limited	20.36	-0.44	-2.10%
AU:PAR	Paradigm Biopharmaceuticals Ltd.	0.24	-0.15	-37.97%
AU:ATH	Alterity Therapeutics Ltd.	0.27	-0.23	-47.00%
AU:ZLD	Zelira Therapeutics Ltd.	0.50	0.15	42.86%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Amplia Therapeutics AI Stock Analysis